Epithelial-to-mesenchymal transition (EMT) causing acquired resistance to afatinib in a patient with epidermal growth factor receptor (EGFR)-mutant lung adenocarcinoma
We report the first case of epithelial-to-mesenchymal transition (EMT) as the cause of acquired resistance to the second-generation EGFR-tyrosine kinase inhibitor (TKI), afatinib in a patient with advanced non-small cell lung cancer (NSCLC) harboring a sensitizing EGFR mutation. Patients with EGFRmu...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Published: |
AME Publishing Company
2018
|
| Subjects: |
| _version_ | 1796961350577029120 |
|---|---|
| author | Poh, Mau Ern Liam, Chong Kin Rajadurai, Pathmanathan Chai, Chee Shee |
| author_facet | Poh, Mau Ern Liam, Chong Kin Rajadurai, Pathmanathan Chai, Chee Shee |
| author_sort | Poh, Mau Ern |
| collection | UM |
| description | We report the first case of epithelial-to-mesenchymal transition (EMT) as the cause of acquired resistance to the second-generation EGFR-tyrosine kinase inhibitor (TKI), afatinib in a patient with advanced non-small cell lung cancer (NSCLC) harboring a sensitizing EGFR mutation. Patients with EGFRmutant NSCLC inevitably develop acquired resistance while on EGFR-TKI treatment. EMT which renders cancer cells more invasive and migratory is one of the mechanisms of acquired resistance to EGFR-TKIs and correlates with a poor prognosis. Possible therapeutic strategies in patients with EMT include blocking M2 muscarinic receptor signalling, targeting EMT with histone deacetylase inhibitors such as entinostat and MEK-inhibitors such as selumetinib, inhibition of microRNAs, immunotherapy and inhibiting fibroblast growth factor receptor-1. |
| first_indexed | 2024-03-06T05:52:56Z |
| format | Article |
| id | um.eprints-21020 |
| institution | Universiti Malaya |
| last_indexed | 2024-03-06T05:52:56Z |
| publishDate | 2018 |
| publisher | AME Publishing Company |
| record_format | dspace |
| spelling | um.eprints-210202021-03-23T02:26:38Z http://eprints.um.edu.my/21020/ Epithelial-to-mesenchymal transition (EMT) causing acquired resistance to afatinib in a patient with epidermal growth factor receptor (EGFR)-mutant lung adenocarcinoma Poh, Mau Ern Liam, Chong Kin Rajadurai, Pathmanathan Chai, Chee Shee R Medicine We report the first case of epithelial-to-mesenchymal transition (EMT) as the cause of acquired resistance to the second-generation EGFR-tyrosine kinase inhibitor (TKI), afatinib in a patient with advanced non-small cell lung cancer (NSCLC) harboring a sensitizing EGFR mutation. Patients with EGFRmutant NSCLC inevitably develop acquired resistance while on EGFR-TKI treatment. EMT which renders cancer cells more invasive and migratory is one of the mechanisms of acquired resistance to EGFR-TKIs and correlates with a poor prognosis. Possible therapeutic strategies in patients with EMT include blocking M2 muscarinic receptor signalling, targeting EMT with histone deacetylase inhibitors such as entinostat and MEK-inhibitors such as selumetinib, inhibition of microRNAs, immunotherapy and inhibiting fibroblast growth factor receptor-1. AME Publishing Company 2018 Article PeerReviewed Poh, Mau Ern and Liam, Chong Kin and Rajadurai, Pathmanathan and Chai, Chee Shee (2018) Epithelial-to-mesenchymal transition (EMT) causing acquired resistance to afatinib in a patient with epidermal growth factor receptor (EGFR)-mutant lung adenocarcinoma. Journal of Thoracic Disease, 10 (7). E560-E563. ISSN 2072-1439, DOI https://doi.org/10.21037/jtd.2018.06.122 <https://doi.org/10.21037/jtd.2018.06.122>. https://doi.org/10.21037/jtd.2018.06.122 doi:10.21037/jtd.2018.06.122 |
| spellingShingle | R Medicine Poh, Mau Ern Liam, Chong Kin Rajadurai, Pathmanathan Chai, Chee Shee Epithelial-to-mesenchymal transition (EMT) causing acquired resistance to afatinib in a patient with epidermal growth factor receptor (EGFR)-mutant lung adenocarcinoma |
| title | Epithelial-to-mesenchymal transition (EMT) causing acquired resistance to afatinib in a patient with epidermal growth factor receptor (EGFR)-mutant lung adenocarcinoma |
| title_full | Epithelial-to-mesenchymal transition (EMT) causing acquired resistance to afatinib in a patient with epidermal growth factor receptor (EGFR)-mutant lung adenocarcinoma |
| title_fullStr | Epithelial-to-mesenchymal transition (EMT) causing acquired resistance to afatinib in a patient with epidermal growth factor receptor (EGFR)-mutant lung adenocarcinoma |
| title_full_unstemmed | Epithelial-to-mesenchymal transition (EMT) causing acquired resistance to afatinib in a patient with epidermal growth factor receptor (EGFR)-mutant lung adenocarcinoma |
| title_short | Epithelial-to-mesenchymal transition (EMT) causing acquired resistance to afatinib in a patient with epidermal growth factor receptor (EGFR)-mutant lung adenocarcinoma |
| title_sort | epithelial to mesenchymal transition emt causing acquired resistance to afatinib in a patient with epidermal growth factor receptor egfr mutant lung adenocarcinoma |
| topic | R Medicine |
| work_keys_str_mv | AT pohmauern epithelialtomesenchymaltransitionemtcausingacquiredresistancetoafatinibinapatientwithepidermalgrowthfactorreceptoregfrmutantlungadenocarcinoma AT liamchongkin epithelialtomesenchymaltransitionemtcausingacquiredresistancetoafatinibinapatientwithepidermalgrowthfactorreceptoregfrmutantlungadenocarcinoma AT rajaduraipathmanathan epithelialtomesenchymaltransitionemtcausingacquiredresistancetoafatinibinapatientwithepidermalgrowthfactorreceptoregfrmutantlungadenocarcinoma AT chaicheeshee epithelialtomesenchymaltransitionemtcausingacquiredresistancetoafatinibinapatientwithepidermalgrowthfactorreceptoregfrmutantlungadenocarcinoma |